Gastric gastrointestinal stromal tumors. Is there a necessity to use imatinib in the intermediate-risk group?

RESEARCH ARTICLE

Hippokratia 2021, 25(3): 113-118

Yalav O, Gumus S, Gul MO, Eray IC, Rencuzogullari A
Department of General Surgery, Department of Surgical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey